SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is generating significant community discussion driven by its integration with World Liberty Financial's $USD1 for payroll and card services, alongside anticipation for its Super App and updated tokenomics. Investors are highlighting its real-world utility in on-chain payroll and payments, emphasizing its ISO 20022 and MiCA compliance, and low dilution as key factors attracting bullish sentiment.

The ticket is $Testicle. EVERY SINGLE ONE OF YOU CAME FROM A $Testicle. $Testicle always bounce.   We have a website on which you can create art or memes. We have a community. We have a raid group. We aim to provide the best testicular care on CT.   We might even have to call on our nefarious leader, Harry Bolz. Alright Chad, SACK TF. Or else you’re a Low T beta male.   If you have questions and or concerns please feel to reach out to a team member on how you can acquire or become a high testosterone male in a sea of betas. I mean how else does one live if not as a High T male?

Testicle

TESTICLE CRYPTO is trending as a highly speculative meme coin, generating significant community buzz, often alongside its related token $BALLSACK. Discussion ranges from humorous "all-in" declarations to widespread criticism regarding the perceived "useless" utility and the overall speculative nature of such projects in the crypto market.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE is generating significant buzz within the crypto community, largely due to its recent listing on MEXC Meme+ and an energetic social presence. Discussions center on its 'AI dog' branding, speculated connection to Grok, and a highly engaged community that views it as a potential standout in the meme coin landscape.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is actively trending as its passionate community relentlessly focuses on building a "permissionless brand" with tangible, real-world products like Kendu Spice and Energy drinks. The discussion centers on the project's consistent IRL initiatives and long-term conviction, with many encouraging accumulation of what they view as a truly dedicated and unique ecosystem.

Ballsackcoin

BALLSACK CRYPTO ($BALLSACK) is trending due to its recent launch, following in the footsteps of the successful $TESTICLE meme coin. The community is actively discussing its purely speculative nature, playfully acknowledging its stated lack of utility but high confidence. This new asset is generating conversation as another highly humorous and volatile meme token within the crypto landscape.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending due to its strengthened balance sheet from a completed pension reversion, fueling investor excitement around its strategic pivot into pharmaceutical API manufacturing and advanced battery materials. The community anticipates significant government contracts related to national security for domestic pharma supply chains, with many expecting a substantial revaluation and a "Kodak moment" surge.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is heavily discussed following its recent shareholder meeting and a significant $200 million investment in Mr. Beast Industries, drawing strong reactions from the community. Many investors are expressing deep concern over the strategic direction, perceived dilution, and no-shows from anticipated high-profile speakers, causing frustration with management's capital allocation. However, a segment of the community views the Mr. Beast partnership as a potential "moonshot" for long-term growth and broader exposure, diversifying its Ethereum-focused treasury.

Constellation Software Inc

Constellation Software (CSU.TSX) is a major talking point as its shares experience a significant drawdown, leading many in the community to see it as a compelling long-term buying opportunity. Despite strong performance metrics like robust revenue growth and free cash flow available to shareholders (FCFA2S), investors are debating the impact of AI on the software sector and where the stock's bottom might be. Bullish analyst ratings and strategic spin-off activities further underscore the firm's enduring acquisition-led growth strategy, which loyal shareholders are confident will prevail.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne (S) is trending following a significant stock drop, fueled by cautious guidance and a CFO departure, despite beating recent EPS and revenue estimates. This has sparked intense community debate, with many investors frustrated by its consistent underperformance relative to a strong cybersecurity sector, yet others view the sell-off as an extreme overreaction, citing strong fundamentals, AI-native security offerings, and a compelling case for a potential acquisition.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy Inc

T1 Energy is trending as it fortifies its standing as a domestic solar manufacturer, securing crucial FEOC compliance and a significant supply deal for its Texas facilities. The community is actively discussing the company's potential undervaluation and its strategic role in addressing the escalating energy demands of AI data centers. Investors view recent capital raises as foundational for its aggressive growth trajectory and market share expansion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Glucotrack Inc. (GCTK), a medical technology company specializing in diabetes management solutions, attracted significant investor interest after its shares rose by over 144% on Friday afternoon.&nbsp;On Thursday, the company announced a new financing arrangement with Sixth Borough Capital Fund LP. This agreement could provide the company with up to $20 million in equity capital over the next two years, depending on various regulatory and market conditions.On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/GCTK">Glucotrack stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume levels also shifted to ‘extremely high’ from ‘low’ levels in the last 24 hours.<figure class="image"><img style="aspect-ratio:942/113;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_12_133920_png_26d362bae8.webp" alt="GCTK’s Sentiment Meter and Message Volume as of 01:30 p.m. ET on Sep. 12, 2025 | Source: Stocktwits" width="942" height="113"><figcaption>GCTK’s Sentiment Meter and Message Volume as of 01:30 p.m. ET on Sep. 12, 2025 | Source: Stocktwits</figcaption></figure>The stock experienced a 1,800% surge in user message count as of Friday morning. Stocktwits users commended the investment move.&nbsp;<stembedurl>https://stocktwits.com/HUBC1/message/628487656</stembedurl><stembedurl>https://stocktwits.com/ArdentInvestor/message/628487338</stembedurl>The deal includes a purchase agreement and a related registration rights agreement. The agreement grants Glucotrack the right, but not the obligation, to issue and sell shares of its common stock valued at up to $20 million. This offering can be executed incrementally, at the company's discretion, within a 24-month window following the commencement date.This financing vehicle provides Glucotrack with a flexible means to raise capital when needed, enabling it to support product development, commercialization, or general operations.&nbsp;For the second quarter, the company’s net loss increased to $4.75 million, compared to a loss of $4.48 million in the same period last year. Cash and equivalents as of June 30 totaled $9.5 million.&nbsp;Glucotrack stock has lost over 97% of its value year-to-date and 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/opendoor-chairman-keith-rabois-plans-massive-layoffs/chw8v8XRdDA">Opendoor Chairman Keith Rabois Plans Massive Layoffs: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Glucotrack Stock Just Rose Over 123% Today: Here’s An Important Update

Glucotrack announced a new financing arrangement with Sixth Borough Capital Fund LP on Thursday.

Equity

Glucotrack announced a new financing arrangement with Sixth Borough Capital Fund LP on Thursday.


Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among healthcare names on Stocktwits.GlucoTrack (GCTK)GlucoTrack posted the highest increase in retail chatter, with message volume surging 3,700% over the past seven days. As of late Sunday, sentiment remained ‘bullish’ among retail traders.On July 8, the company announced the repurchase of over 90% of its Series A Warrants, funded with cash on hand.&nbsp;The move followed last month’s disclosure of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glucotrack-announces-positive-results-from-implantable-blood-glucose-monitor-study/chmJoJwRREo">positive results</a> from its first-in-human clinical study of its continuous blood glucose monitor (CBGM).The implantable device demonstrated 99% data capture, strong accuracy, and no serious adverse events. Designed for a three-year lifespan, the CBGM measures blood glucose directly, not interstitial fluid, and requires no on-body wearable.&nbsp;A long-term feasibility study is expected to launch in Q3 2025.<a href="https://stocktwits.com/symbol/GCTK">GCTK’s stock</a> has declined 98.5% so far in 2025.Sarepta Therapeutics (SRPT)Sarepta saw a 1,991% increase in message volume over the past week, with sentiment remaining ‘extremely bullish’ as of late Sunday, despite mounting regulatory concerns.On July 19, shares plunged over 26% in midday trading after FDA Commissioner Marty Makary said the agency is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-taking-a-hard-look-to-at-whether-sarepta-gene-therapy-elevidys-should-remain-on-the-market/ch8kDByR5qt">“taking a hard look”</a> at whether Sarepta’s gene therapy, Elevidys, should stay on the market.The company disclosed a third patient death on July 18, involving a 51-year-old participant in a limb-girdle muscular dystrophy trial using a similar viral vector to Elevidys. Two earlier deaths were already under FDA investigation. Reuters reported the agency plans to request a voluntary halt to Elevidys' shipments.Amid the fallout,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">analysts criticized Sarepta</a> for not disclosing the fatality earlier, particularly during a recent business update where it announced a 500-job layoff and $400 million in cost cuts.&nbsp;The company has since paused shipments to non-ambulatory patients and&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-surges-after-hours-as-it-slashes-500-jobs-amid-fda-black-box-warning-for-gene-therapy-retail-eyes-rebound/ch8KR0HR5oM">agreed to a black box warning</a> for Elevidys, citing the risk of acute liver failure.<a href="https://stocktwits.com/symbol/SRPT">SRPT’s stock</a> has declined 88.7% so far in 2025.TNF Pharmaceuticals (TNFA)TNF Pharma recorded a 1,900% rise in message volume over the past seven days on Stocktwits, with sentiment labeled ‘extremely bullish’ as of late Sunday.Although there was no specific news catalyst driving the buzz last week, the momentum has been strong since last month when TNFA announced a Compassionate Use collaboration with the DADA2 Foundation to study isomyosamine as a treatment for DADA2, a rare pediatric autoinflammatory disorder.In April,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tnf-pharmaceuticals-to-use-ai-to-recruit-patients/chQSz8ARbXp">TNFA partnered with Renova Health</a> to apply AI and machine learning to optimize patient recruitment. The company is analyzing data from 30,000 patients to identify high-risk cohorts, particularly for interventions related to inflammation and side effects of GLP-1 therapy.TNFA’s pipeline includes two drug platforms: isomyosamine, which regulates inflammatory pathways, and Supera-CBD, which targets chronic pain, addiction, and epilepsy.<a href="https://stocktwits.com/symbol/TNFA">TNFA’s stock</a> has declined 92.4% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amazon-stealthily-hiked-prices-on-everyday-essentials-as-trump-tariffs-bit-report/ch8qvlTR5Ae">Amazon Stealthily Hiked Prices On Everyday Essentials As Trump Tariffs Bit: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

GlucoTrack (GCTK), Sarepta Therapeutics (SRPT), and TNF Pharmaceuticals (TNFA) recorded the highest increases in message volume among healthcare names on Stocktwits. (Photo credit: Getty Images)

GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why

GlucoTrack repurchased over 90% of its Series A warrants, while Sarepta disclosed a third patient death, suspended Elevidys shipments, and added a black-box warning amid FDA scrutiny.

Shares of Glucotrack, Inc. (GCTK) traded 32% higher on Wednesday afternoon after the company announced that its first-in-human clinical study for its investigational continuous blood glucose monitor (CBGM) yielded positive results.The medical device company’s CBGM demonstrated excellent accuracy, a 99% data capture rate, and no procedure or device-related serious adverse events, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://glucotrack.com/glucotrack-and-onetwo-analytics-present-positive-final-results-of-first-in-human-study-for-continuous-blood-glucose-monitor-at-american-diabetes-associations-85th-scientific-sessions/">said</a>.Glucotrack’s CBGM is a long-term, implantable system that continually measures glucose from blood rather than interstitial fluid with a sensor designed for a 3-year life and no on-body wearable component.It aims to eliminate the lag time associated with traditional continuous glucose monitoring systems and is connected to subcutaneous electronics that communicate with a mobile application.The in-human study for the CBGM was conducted between Dec. 13, 2024, and Jan. 31, 2025, and included ten participants with either Type 1 or Type 2 diabetes who were on intensive insulin therapy.The insertion and removal procedures were performed by interventional cardiologists.Following the device placement, each participant underwent inpatient observation for 4 days. During this period, frequent blood sampling and glucose tolerance tests were conducted to assess device performance.The system remained in place throughout the study period and was removed successfully at study completion, with patients then followed for 7 days post-removal.Glucotrack now expects to initiate a long-term early feasibility study in Q3 2025, which will evaluate safety and performance of the monitor over an extended period.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GCTK">GCTK</a> soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours to its highest levels in 3 months while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_25_at_12_52_09_PM_png_991ddcc4e4.webp" alt="GCTK's Sentiment Meter and Message Volume as of 12:50 p.m. ET on June 25, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>GCTK's Sentiment Meter and Message Volume as of 12:50 p.m. ET on June 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for Glucotrack being approached by big pharmaceutical companies for either purchase or partnerships following the news.<stembedurl>https://stocktwits.com/Barrister/message/618976594</stembedurl>GCTK stock is down by about 98% this year and has erased nearly all of its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-stock-slumps-after-fda-opens-probe-into-patient-death-analyst-sounds-alarm/chmJnVnRREn">Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A woman holds an insulin pen with an exposed injection needle. Photo: Hannes P. Albert/dpa (Photo by Hannes P Albert/picture alliance via Getty Images)

Glucotrack Announces Positive Results From Its Implantable Blood Glucose Monitor Study: Retail Sentiment Hits 3-Month High

The company’s continuous blood glucose monitor demonstrated excellent accuracy, a 99% data capture rate, and no procedure or device-related serious adverse events, the company said.

Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GCTK
GlucoTrack Inc

Feed

News

Sentiment

Fundamentals

Info

Latest GCTK News

GCTKGlucoTrack Inc